Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-140339

Published: 2020

Journal Articles

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

Marta Alonso Fernández de Gatta, MD PhD, Ana Martín García, MD PhD, Félix López Cadenas, MD, Díaz Peláez Elena, MD, Tamara Jimenez, Jesus Maria . Hernández-Rivas, MD, Victor Vallejo García, MD, Manuel Barreiro Pérez, MD, Lucia Rodríguez Estévez, MD, Juan Carlos Castro Garay, Diego Ávila, MD, Adolfo Alejandro Cabanillas Cabral, MD, Clara Sánchez Pablo, MD, María Díez-Campelo, MD PhD, Pedro Luís Sánchez Fernández, MD PhD

Blood (2019) 134 (Supplement_1): 1727.

https://doi.org/10.1182/blood-2019-127938

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

María Zurdo, Ana M Hurtado López, Tzu Hua Chen-Liang, Helios Martínez-Banaclocha, Laura Palomo, Félix López Cadenas, MD, Eva Lumbreras, Blanca Xicoy, MD MSc, Lurdes Zamora, PhD, María Díez-Campelo, MD PhD, Francesc Sole, PhD, Pablo Pelegrín, Andres Jerez

Blood (2019) 134 (Supplement_1): 2991.

https://doi.org/10.1182/blood-2019-128094

Published: 2019

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Journal Articles

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 841.

https://doi.org/10.1182/blood-2019-123064

Published: 2019

Journal Articles

Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes

Blood (2019) 134 (Supplement_1): 4226.

https://doi.org/10.1182/blood-2019-127204

Published: 2019

Journal Articles

Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications

Vera Adema, PhD, Laura Palomo, Cassandra M Kerr, MS, Wencke Walter, PhD, Bartlomiej Przychodzen, Stephan Hutter, PhD, Thomas Laframboise, PhD, María Díez-Campelo, MD PhD, Mar Mallo, PhD, Aziz Nazha, MD, Blanca Xicoy, MD MSc, Manja Meggendorfer, PhD, Hetty E. Carraway, MD MBA, Claudia Haferlach, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Torsten Haferlach, MD, Francesc Sole, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4221.

https://doi.org/10.1182/blood-2019-129292

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation

Blood (2019) 134 (Supplement_1): 2687.

https://doi.org/10.1182/blood-2019-131733

Published: 2019

Journal Articles

Transcriptional Regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome Reveals DDIT3 As a Potential Driver of Transformation

Blood (2019) 134 (Supplement_1): 3764.

https://doi.org/10.1182/blood-2019-122686

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

Alvaro Veiga, MD, Alba Redondo, MD, Miriam López-Parra, MD, Olga López-Villar, MD, Eva Villarón, Maria Díez-Campelo, MD PhD, Daniel Rivera, MD, Natalia Espinosa, MD, Nerea Arratibel, MD, Mónica Baile, MD, Estefania Pérez-López, MD, Mónica Cabrero, MD, Ana A. Martín, MD, Lourdes Vázquez, MD, Lucía López Corral, MD, Dolores Caballero, MD PhD, Consuelo Del Cañizo, MDPhD, Fermin Sanchez-Guijo, MD PhD

Blood (2017) 130 (Supplement 1): 1981.

https://doi.org/10.1182/blood.V130.Suppl_1.1981.1981

Published: 2017

Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 4256.

https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256

Published: 2017

Journal Articles

Analysis of Transfusion Dependency Development and Disease Evolution in Patients with MDS with 5q- and without Transfusion Needs at Diagnosis

Blood (2016) 128 (22): 3180.

https://doi.org/10.1182/blood.V128.22.3180.3180

Published: 2016

Journal Articles

New Score Prognostic System for Patients with MDS and Intermediate IPSS-R: Novel Algorithm to Distinguish Between Low and High Risk in This Subset of Patients. Results from the Spanish Group of MDS (GESMD). Gesmdi Score

Blood (2016) 128 (22): 4323.

https://doi.org/10.1182/blood.V128.22.4323.4323

Published: 2016

Journal Articles

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

María Díez Campelo, MD PhD, Julio Davila, MD, Sanchez Barba Mercedes, MD, Maria Lopez-Pavia, MD, Esperanza Such, PhD, Teresa Bernal, MD, Elisa Luño, Fernando Ramos, Marisa Calabuig, MD, Helena Pomares, MD, Bernardo Gonzalez, Brayan Merchan, MD, Edgardo Barranco, MD, Reyes Sancho Tello, Marta Callejas, Maria Jose Requena, María José Jiménez, Maria Pedreño, Angeles Medina, MD, Ana I Vicente, PhD, Andrea Campeny, Montse Cortes Sansa, Carmen Pedro, MD, Jose Falantes, MD, Maria Jesus Arilla, Abelardo Bárez, MD, Regina Garcia, MD, Maria Jose Arcos, Valle Gomez, Carolina Muñoz, Carlos Cervero, MD, Javier Casaño, Raquel De Paz, Luz Amigo, Andres Insunza, Juan Antonio Muñoz, Maria Teresa Cedena, Marta Gomez, Patricia Font, Raquel Del Campo, Carlos Fernandez Lago, Jose Antonio Gonzalez Hurtado, Maria Dolores Linares Latorre, Asuncion Mora Casado, Maria Vahi, MD PhD, Luis Benlloch, Guillermo Sanz, MD PhD, María Consuelo Cañizo, MD PhD

Blood (2015) 126 (23): 2896.

https://doi.org/10.1182/blood.V126.23.2896.2896

Published: 2015

Journal Articles

RAEB-1 with Erythroid Hyperplasia and Erythroleukemia Share Clinico-Biological Features and Outcome: A Same Disease with Different Labels?

Xavier Calvo, MD, Leonor Arenillas, MD, Mar Tormo, MD PhD, David Valcárcel, MD PhD, Elisa Luño, MD PhD, Esther Alonso, MD, María Díez-Campelo, MD PhD, Fernando Ramos, MD PhD MPH, Carmen Pedro, MD PhD, Beatriz Arrizabalaga, MD, Alicia Bailén, MD, José María Raya, MD, María Teresa Ardanaz, MD, Guillermo Sanz, MD PhD, Lourdes Florensa, MD PhD

Blood (2015) 126 (23): 2866.

https://doi.org/10.1182/blood.V126.23.2866.2866

Published: 2015

Journal Articles

Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes

David Valcarcel, MD PhD, Amit Verma, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Aristoteles Giagounidis, MD, María Díez-Campelo, MD PhD, Jan Janssen, MD, Richard F. Schlenk, MD, Gianluca Gaidano, MD PhD, Jaime Perez de Oteyza, MD, Ann L Cleverly, MD, Alan Y Chiang, PhD, Michael Lahn, MD, Durisala Desiaih, PhD, Susan C. Guba, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 1669.

https://doi.org/10.1182/blood.V126.23.1669.1669

Published: 2015

NARROW

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes

Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications

Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation

Transcriptional Regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome Reveals DDIT3 As a Potential Driver of Transformation

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Analysis of Transfusion Dependency Development and Disease Evolution in Patients with MDS with 5q- and without Transfusion Needs at Diagnosis

New Score Prognostic System for Patients with MDS and Intermediate IPSS-R: Novel Algorithm to Distinguish Between Low and High Risk in This Subset of Patients. Results from the Spanish Group of MDS (GESMD). Gesmdi Score

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

RAEB-1 with Erythroid Hyperplasia and Erythroleukemia Share Clinico-Biological Features and Outcome: A Same Disease with Different Labels?

Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only